Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Director/PDMR Shareholding

4 Jan 2022 09:27

RNS Number : 3367X
IQ-AI Limited
04 January 2022
 

4 January 2022

IQ-AI Ltd

("IQ-AI" or the "Company")

 

Director/PDMR Shareholding

 

IQ-AI announces that Michael Schmainda, Director of IQAI and CEO of Imaging Biometrics, has been granted an option to subscribe for 5,969,792 ordinary shares of 1p each in the Company ("Ordinary Shares") at an exercise price of 5.88p per share. The option will vest on 15 December 2024.

 

Michael Schmainda is currently interested in 9,108,400 Ordinary Shares, representing 4.99 per cent. of the voting rights of the Company.

 

The Directors of the Company accept responsibility for the contents of this announcement

 

-ENDS-

 

For further information, please contact:

IQ-AI Limited

Trevor Brown/Brett Skelly/Vinod Kaushal

Tel: 020 7469 0930

 

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Michael Schmainda

2

Reason for the notification

a)

Position/status

Director of the Company

b)

Initial notification /Amendment

 

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

IQ-AI Limited

b)

LEI

213800SPW48XRJS2QH57

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 1p each

 

 

 

 

 

ISIN: JE00BD4H0R42

b)

Nature of the transaction

Grant of Option

 

c)

Price(s) and volume(s)

5,969,792 ordinary shares at 5.88p per share

 

d)

Aggregated information

- Aggregated volume

- Price

 

 

N/A (single transaction)

 

e)

Date of the transaction

15 December 2021

 

f)

Place of the transaction

N/A

 

 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law (as defined in the European Union (Withdrawal) Act 2018).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEANFLEADAEEA
Date   Source Headline
20th Nov 20209:00 amRNSPrice Monitoring Extension
17th Nov 20201:26 pmRNSDirector/PDMR Shareholding
13th Nov 202011:05 amRNSSecond Price Monitoring Extn
13th Nov 202011:00 amRNSPrice Monitoring Extension
12th Nov 20204:41 pmRNSSecond Price Monitoring Extn
12th Nov 20204:36 pmRNSPrice Monitoring Extension
12th Nov 20202:01 pmRNSPrice Monitoring Extension
12th Nov 20207:00 amRNSCorrection: Director Dealing and CLN Conversion
11th Nov 20207:00 amRNSDirector Dealing and Conversion of Loan Notes
10th Nov 20204:35 pmRNSPrice Monitoring Extension
10th Nov 20202:06 pmRNSSecond Price Monitoring Extn
10th Nov 20202:00 pmRNSPrice Monitoring Extension
10th Nov 202011:06 amRNSSecond Price Monitoring Extn
10th Nov 202011:01 amRNSPrice Monitoring Extension
9th Nov 20202:06 pmRNSSecond Price Monitoring Extn
9th Nov 20202:00 pmRNSPrice Monitoring Extension
9th Nov 202011:05 amRNSSecond Price Monitoring Extn
9th Nov 202011:00 amRNSPrice Monitoring Extension
9th Nov 20209:05 amRNSSecond Price Monitoring Extn
9th Nov 20209:00 amRNSPrice Monitoring Extension
9th Nov 20207:00 amRNSIB and the Mayo Clinic enter into an Agreement
6th Nov 20204:35 pmRNSPrice Monitoring Extension
6th Nov 20202:05 pmRNSSecond Price Monitoring Extn
6th Nov 20202:00 pmRNSPrice Monitoring Extension
6th Nov 202011:05 amRNSSecond Price Monitoring Extn
6th Nov 202011:00 amRNSPrice Monitoring Extension
5th Nov 20204:41 pmRNSSecond Price Monitoring Extn
5th Nov 20204:36 pmRNSPrice Monitoring Extension
5th Nov 20209:00 amRNSPrice Monitoring Extension
5th Nov 20207:00 amRNSMontgomery Cancer Center Purchases IB's Software
4th Nov 20207:00 amRNSLSN Software Receives FDA Clearance
30th Oct 202011:05 amRNSSecond Price Monitoring Extn
30th Oct 202011:00 amRNSPrice Monitoring Extension
30th Oct 20207:00 amRNS"Gad Free" Imaging moves to Validation Testing
15th Oct 20207:00 amRNSIB Stroke
8th Oct 20203:41 pmRNSStoneChecker Update
24th Sep 202010:43 amRNSThe Benefits and Significance of IB Neuro
16th Sep 20207:00 amRNSKeck Medical Centre of USC Purchases IB's Software
10th Sep 20207:00 amRNSIB Trax™
4th Sep 20209:03 amRNS“Gad Free” Imaging - One Step Closer
7th Aug 20207:00 amRNSHalf-year Report
5th Aug 20204:41 pmRNSSecond Price Monitoring Extn
5th Aug 20204:35 pmRNSPrice Monitoring Extension
5th Aug 202011:05 amRNSSecond Price Monitoring Extn
5th Aug 202011:00 amRNSPrice Monitoring Extension
5th Aug 20209:53 amRNSStonechecker Update
27th Jul 20207:00 amRNSUpdate - IB Stroke
10th Jul 20207:00 amRNSNew Development Aims to Detect Tumor Infiltration
19th Jun 20207:00 amRNSIB, the Recognised National Standard in MRI DSC
15th Jun 202011:52 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.